Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[haysaw]

Nobody wants the stock because the company might not have a means of income shortly and their sales have stagnated.

I don't think this is accurate. You are looking at the company from the wrong business angle, insofar as they are transforming themselves into a biotech R&D company. Certainly, sales growth would help infuse capital and make secondary offerings and dilutions less of a necessity, which would benefit shareholders more, but the lack of revenue now is no longer the driving force for the investment performance in the long run.